ENV-294
Phase 2 registry
Since , the date of the source that reports this phase.
Summary
ENV-294 is a program from Enveda. It is being developed for atopic dermatitis; asthma. ClinicalTrials.gov lists it at Phase 2 (recruiting) under NCT07643766, NCT07298395, NCT07301255, NCT07336940. The AI role named in the source is molecule discovery. Registry records: NCT07643766, Phase 2, recruiting, updated Aug 6, 2026; NCT07298395, Phase 2, recruiting, updated Sep 25, 2026; NCT07301255, Phase 2, recruiting, updated Sep 24, 2026; NCT07336940, Phase 1, completed, updated Apr 1, 2026. About the company, based in United States: AI and metabolomics platform that decodes natural chemistry to find new small-molecule medicines; lead ENV-294 is in Phase 2 for atopic dermatitis and asthma. The latest dated source is from Sep 23, 2026.
Built only from the sources listed on this page.
Facts
- Company
- Enveda
- Indication
- Atopic dermatitis; asthma
- Therapeutic area
- Immunology and inflammation
- AI role
- Molecule discovery
- Phase in the source
- Phase 2, as of Sep 23, 2026
- Phase source
- Registry
- Board column
- Phase 2
AI evidence
AI source: Company
“based off of a molecule discovered in nature using AI and adapted with modern medicinal chemistry.”
Trial records
- NCT07643766 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT07298395 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT07301255 on ClinicalTrials.gov (opens in new tab) Phase 2 Recruiting Updated
- NCT07336940 on ClinicalTrials.gov (opens in new tab) Phase 1 Completed Updated
Milestone timeline
-
NCT07336940 record updated
Phase 1, Completed
-
NCT07643766 record updated
Phase 2, Recruiting
-
ClinicalTrials.gov record: Phase 2
-
NCT07301255 record updated
Phase 2, Recruiting
-
NCT07298395 record updated
Phase 2, Recruiting
-
Registry check
all four listed trials (NCT07643766, NCT07298395, NCT07301255, NCT07336940) are ENV-294 studies (three Phase 2 in atopic dermatitis and asthma, one completed Phase 1). ENV-308 has its own entry.
NCT07643766 (opens in new tab)NCT07298395 (opens in new tab)NCT07301255 (opens in new tab)NCT07336940 (opens in new tab)
About Enveda
AI and metabolomics platform that decodes natural chemistry to find new small-molecule medicines; lead ENV-294 is in Phase 2 for atopic dermatitis and asthma.
Spot an error? Tell me and I'll fix it.